Codex DNA Launches New Automated Synthetic Biology Workstation for Commercial Use
August 18, 2020 09:15 ET | Codex
San Diego, Aug. 18, 2020 (GLOBE NEWSWIRE) -- The new BioXp™ 3250 system – a fully automated, benchtop platform for synthetic biology workflows – dramatically accelerates the development of critical...
emergent logo.jpg
Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate
July 27, 2020 06:30 ET | Emergent BioSolutions
Emergent will provide contract development and manufacturing services beginning in 2020 to produce drug substance at large scale for commercial supplyAgreement is valued at approximately $174 million...
BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines
May 13, 2020 07:00 ET | The Sabin Vaccine Institute
WASHINGTON, D.C. and ROME, Italy, May 13, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and...
Akers Bio logo
Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19
April 06, 2020 09:25 ET | Akers Biosciences Inc.
Successfully obtained clones for all three selected Coronavirus Antigens Thorofare, New Jersey, April 06, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a...
SGI-DNA is now Codex
April 06, 2020 09:07 ET | SGI-DNA
San Diego, April 06, 2020 (GLOBE NEWSWIRE) -- SGI-DNA, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, the BioXp™ 3200 system, today announced the...
emergent logo.jpg
Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
March 31, 2020 16:05 ET | Emergent BioSolutions
CDMO agreement for NanoFlu to support pathway to licensureExpanded collaboration now includes NanoFlu and COVID-19 vaccine candidate GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent...
emergent logo.jpg
Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
January 13, 2020 06:40 ET | Emergent BioSolutions
GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed...
emergent logo.jpg
Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
November 22, 2019 08:19 ET | Emergent BioSolutions
GAITHERSBURG, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and...
emergent logo.jpg
Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate
October 10, 2019 06:38 ET | Emergent BioSolutions
GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate,...
Batavia Biosciences partners with the University of Tokyo to develop a vector-based vaccine against Nipah virus
May 14, 2019 07:00 ET | Batavia Biosciences B.V.
Leiden, the Netherlands, May 14, 2019 – Batavia Biosciences announced today that it will work together in a consortium including the European Vaccine Initiative and Stanford University, icddr,b, and...